ADVANCED MALIGNANT SOLID NEOPLASM

This study tests a daily pill called osimertinib in people with advanced cancers that have certain EGFR gene changes. The drug blocks a faulty protein that helps tumors grow. Researchers want to see if it can shrink tumors or slow the disease in 19 patients with various cancer ty…

This study tests a drug called binimetinib in 53 adults with advanced cancers that have a specific genetic change (NRAS mutation). The drug blocks proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from growing. This is a phase II trial f…

This study tests a drug called erdafitinib in people with advanced cancers that have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. The goal is to see if it can shrink tumors or stop them from getting worse for at least 6 months. About 35 …

This study tested the drug crizotinib in 4 people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called ROS1 translocation. The drug blocks a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or st…

This study tests a drug called GSK2636771 in 35 adults with advanced cancers that have lost a protein called PTEN. The drug blocks a growth signal that these cancer cells rely on. Researchers want to see if it can shrink tumors or stop them from growing. This is a phase II trial,…

This early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…

This study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…

This study tests a drug called MLN0128 (TAK-228) in people with advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. About 49 participants will receive the treatment to see if it can shrin…

This early-phase study tests a new drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially bladder cancer. The main goals are to find the safest dose and understand side effects. About 7…

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that tell cancer cells to grow. The goal is to see if the drug can shrink or slow the cancer. About 10 adults with certain lymphom…

This study tests a drug called larotrectinib in people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug blocks a faulty protein that helps cancer cells grow. About 35 adults with various solid tumors or lymphomas that haven't responded to …

This early-phase trial tests the safety and best dose of combining two drugs—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, or prostate or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. Abo…

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA gene mutation. The drug blocks a protein that cancer cells need to grow. The goal is to see if the drug can shrink tumors or stop them from growing. About 35 adults with various advanced cancers a…

This study tests whether adding the experimental drug TRC102 to standard chemotherapy (cisplatin and pemetrexed) can shrink tumors or slow cancer growth in people with advanced solid tumors or mesothelioma that have not responded to prior treatments. About 30 adults will take par…

This study tests a drug called crizotinib in people with advanced cancers that have a specific genetic change called MET exon 14 deletion. The drug blocks enzymes that help cancer cells grow and spread. About 20 participants will receive the treatment to see if their tumors shrin…

This early-phase study tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 adults with advanced solid tumors that have stopped responding to standard treatments. The drug is wrapped in a special polymer to help it reach deeper into cancer cells while spari…

This early-phase trial tests a combination of three drugs (copanlisib, olaparib, and durvalumab) in people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to find the safest dose and see if the drugs shrink tumors. About 39 adults with spe…

This study tests a drug called MLN0128 (TAK-228) in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an mTOR mutation. The drug works by blocking enzymes that cancer cells need to grow. The goal is to see if the drug can s…

This study tests a drug called GSK2636771 in people with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from grow…

This study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF genetic changes (non-V600 mutations or fusions). The goal was to see if trametinib could shrink or stop cancer growth by blocking certain proteins. While the treatment may help contro…

This study tests whether the drug olaparib can shrink or slow the growth of advanced solid tumors that have IDH1 or IDH2 gene mutations, including certain brain tumors (gliomas) and bile duct cancers (cholangiocarcinoma). About 89 adults whose cancer has spread or not responded t…

This early-phase trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed by surgery. The stud…

This study is for people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an NF2 mutation. The drug defactinib works by blocking a protein (FAK) that helps these cancer cells grow. Researchers want to see if the drug can shrink tumo…

This study tests a drug called palbociclib in 43 patients with advanced or hard-to-treat cancers that have specific changes in the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to grow. The main goal is to see if the drug can shrink tumors or stop …

This study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…

This study tests a drug called pembrolizumab (Keytruda) in 157 people with rare cancers that have spread or cannot be removed. The drug helps the immune system fight cancer by blocking a protein that tumors use to hide. The main goal is to see if the drug can stop the cancer from…

This study tests a drug called copanlisib in 35 adults with advanced or treatment-resistant cancers that have a specific change in the PTEN gene. The drug blocks a protein that helps cancer cells grow, aiming to shrink tumors or stop them from spreading. The main goal is to see h…

This early-phase trial studies the safety and best dose of two drugs, riluzole and sorafenib, given together to adults with advanced solid tumors or melanoma that has spread and is no longer responding to standard treatments. The goal is to find a dose that limits side effects wh…

This study tests the drug crizotinib in people whose advanced or treatment-resistant solid tumors, lymphoma, or multiple myeloma have a specific genetic change called MET amplification. Crizotinib works by blocking signals that help cancer cells grow and spread. The main goal is …

This early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that have specific genetic mutations. The goal was to find the best dose and check for side effects. The approach aims to shrink or stabilize tumor…

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer that responded to initial chemotherapy. The goal is to find the safest dose and see if the combo helps keep can…

This study tests a drug called afatinib in 19 adults with advanced cancers (like lymphoma or solid tumors) that have a specific EGFR gene mutation and have stopped responding to standard treatments. Afatinib works by blocking the faulty EGFR protein that helps cancer cells grow. …

This study tests a drug called trametinib in 50 adults with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. Par…

This early-stage trial tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This study tests whether adding panitumumab to sotorasib works better than sotorasib alone for people with advanced solid tumors that have a specific KRAS G12C mutation. About 105 adults will take part. The goal is to see if the combination can slow tumor growth or shrink tumors.

This study tests a drug called ulixertinib in people with advanced cancers that have certain changes in the BRAF gene (mutations or fusions). The drug works by blocking signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that h…

This study tests a drug called taselisib in people whose cancer has a specific genetic change (PIK3CA mutation) but not certain other changes. The drug aims to block a protein that helps cancer grow. About 70 adults with advanced solid tumors or lymphomas that haven't responded t…

This study tests two targeted drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific BRAF gene mutation (V600E or V600K). The goal is to see if the combination can shrink tumors or stop them from growing. About 44 adults with various cancer types (…

This early-phase study tests the safety and best dose of the drug neratinib combined with everolimus, palbociclib, or trametinib in people with advanced solid tumors that have not responded to standard treatments. Participants must have certain gene changes (EGFR, HER2, HER3, HER…

This study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had come back or were not responding to treatment. The drug targets cancers with specific changes in FGFR genes. The main goal was to see if the drug could shrink tumors. About 2…

This study tests the drug trametinib in people with advanced cancers that have GNAQ or GNA11 gene mutations. Trametinib blocks certain proteins that help these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from getting worse. Only 4 patients too…

This study tests a drug called ipatasertib in 35 people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an AKT mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the tumors shrin…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This study tests a drug called palbociclib in 40 adults with advanced cancers that have extra copies of the CCND1, 2, or 3 genes. The drug blocks certain proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse.

This study tested a drug called crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink tumors or stop them from growing. Only 5 patients took part, and the results help researchers unde…

This early-phase trial tests a combination of three drugs (dasatinib, temsirolimus, and cyclophosphamide) in children and young adults (ages 1 to 21) with advanced solid tumors that have come back or not responded to standard treatment. The main goals are to find the safest dose …

This early-phase trial tests a new type of treatment that uses small pieces of RNA to block a gene called EphA2, which helps tumors grow. The study includes 49 adults with advanced solid tumors that have spread or come back. The main goals are to find the safest dose and to see w…

This study tests a drug called telaglenastat (CB-839) in adults with advanced solid tumors or malignant peripheral nerve sheath tumors that have certain gene mutations (NF1, KEAP1/NRF2, or LKB1). The drug works by blocking an enzyme cancer cells need to grow. Researchers want to …

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other drugs and radiation in people with advanced cancers that have not responded to standard treatments. About 173 adults with various solid tumors, including prostate cancer, will re…

This study tests a drug called afatinib in 40 patients whose advanced cancers have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or slo…

This study tests a drug called ado-trastuzumab emtansine in people with advanced cancers that have too many HER2 receptors (HER2 amplification), except breast and stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Rese…

This study tests a combination of three drugs (copanlisib, nivolumab, and ipilimumab) in adults with advanced solid tumors that have specific gene changes (PIK3CA or PTEN). The goal is to see if adding copanlisib to standard immunotherapy works better at controlling tumor growth.…

This study tests a drug called copanlisib in people whose advanced cancers have a specific genetic change (PIK3CA mutation). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with var…

This study tested a drug called AZD5363 in 35 people with advanced cancers that have a specific genetic change (AKT mutation). The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is…

This study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific changes in the SMO or PTCH1 genes. The drug blocks a protein that helps cancer grow. The goal is to see if the drug ca…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …

This study tests whether an open labeled placebo—a pill with no active drug that patients know is a placebo—can reduce severe fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply be…

This study looks at whether adding a steroid called dexamethasone to a physical activity program can ease severe tiredness in people with advanced cancer. About 99 patients with fatigue lasting at least 2 weeks will take part. The goal is to see if the combination is practical an…

This study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can ease severe fatigue in people with advanced solid tumors that cannot be cured. About 129 participants will receive the combination for several weeks, and researchers…

This study looks at whether a technology-enhanced symptom monitoring program, combined with regular clinic visits and remote care, can improve quality of life for people with advanced solid tumors who are also in phase 1 immunotherapy trials. About 119 patients with high symptom …

This study compares two drugs—olanzapine and megestrol acetate—to see which works better for improving appetite and preventing weight loss in people with advanced cancer. About 227 patients will take one of the two medications for four weeks. The goal is to find a more effective …

This study is testing a mindfulness program specially adapted for Latino cancer patients and their family caregivers. The goal is to see if it helps reduce stress, anxiety, and improve mental well-being. About 68 patient-caregiver pairs will take part, and researchers will measur…

This study tests a virtual group therapy program for caregivers of people with advanced cancer or serious life-limiting illness. The therapy helps caregivers connect to meaning and purpose, aiming to reduce feelings of hopelessness and burden. The study will enroll 80 caregivers …

This study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will be involved, and their doctors will either use the…

This early-phase trial looks at how DS-8201a works in patients with advanced HER2-positive solid tumors that have spread or cannot be removed. The drug targets a protein on cancer cells to damage their DNA and kill them. Researchers will compare tumor samples taken before and aft…

This study looks at how often cancer patients in a supportive care clinic experience cachexia (unintentional weight loss and loss of appetite) and the emotional burden it places on both patients and their primary caregivers. Researchers will track weight changes and use questionn…

This study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…

This study looks at two different ways to provide palliative care—a special type of care that helps with symptoms and stress—to people with advanced cancer and their caregivers. One method uses a virtual learning group, and the other uses one-on-one technical help. The goal is to…

This study surveys 117 advanced cancer patients to learn if they have talked with family about managing their social media accounts after death. The goal is to understand patient needs and reduce stress around digital legacy. Participants are adults who have used social media and…